Manulife Financial Corporation : Increase of volatility
Entry price | Target | Stop-loss | Potential |
---|
CA$19.6 |
CA$22.3 |
CA$18.2 |
+13.78% |
---|
Manulife Financial Corp. shares have been in strong demand lately. The technical chart pattern looks positive which may give rise to new gains.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths● The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
● With a P/E ratio at 12.82 for the current year and 8.82 for next year, earnings multiples are highly attractive compared with competitors.
● This company will be of major interest to investors in search of a high dividend stock.
● Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
● Over the past year, analysts have regularly revised upwards their sales forecast for the company.
● Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses● Technically, the stock approaches a strong medium-term resistance at CAD 20.93.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.